指南第408号:妊娠滋养细胞疾病的管理
本指南由加拿大妇产科医师学会发布,旨在帮助医疗提供者及时诊断妊娠滋养细胞疾病、规范治疗和随访,并确保恶性或转移性疾病患者早期获得专科诊疗。指南适用于育龄期妊娠滋养细胞疾病女性,建议诊断后转诊妇科评估并考虑初次手术(子宫排空或子宫切除术)和随访;妊娠滋养细胞肿瘤应转诊妇科肿瘤专科进行分期、风险评分并考虑初次手术或全身治疗(单药或多药化疗),所有病例应在多学科肿瘤病例会议上讨论并登记于集中数据库。证据检索自2002年起,共识别673项研究,引用79项,证据质量采用GRADE框架评级。
要点
- 妊娠滋养细胞疾病患者应转诊妇科医生进行初步评估,并考虑初次手术(子宫排空或子宫切除术)和随访。
- 妊娠滋养细胞肿瘤患者应转诊妇科肿瘤专科医生进行分期、风险评分,并考虑初次手术或全身治疗(单药或多药化疗)。
- 所有妊娠滋养细胞肿瘤病例应在多学科肿瘤病例会议上讨论,并登记于集中(区域和/或国家)数据库。
- 本指南适用于急诊科医师在内的多学科医疗提供者,旨在确保恶性或转移性疾病患者早期获得专科诊疗。
- 证据质量采用GRADE方法框架评级,具体推荐等级见原文括号内标注。
适用人群与场景
- 育龄期妊娠滋养细胞疾病女性。
- 目标用户包括急诊科医师、妇产科医生、家庭医生、助产士、麻醉科医生、放射科医生、病理科医生、护士、执业护士、住院医师、妇科肿瘤医生、肿瘤内科医生、放射肿瘤医生、外科医生、肿瘤全科医生、肿瘤科护士、药师、医师助理及其他治疗妊娠滋养细胞疾病的医疗提供者。
处置流程与药物剂量
- 诊断妊娠滋养细胞疾病后应转诊妇科医生进行初步评估,并考虑初次手术(子宫排空或子宫切除术)和随访。
- 诊断妊娠滋养细胞肿瘤后应转诊妇科肿瘤专科医生进行分期、风险评分,并考虑初次手术或全身治疗(单药或多药化疗),可能需要额外治疗。
- 所有妊娠滋养细胞肿瘤病例应在多学科肿瘤病例会议上讨论,并登记于集中(区域和/或国家)数据库。
研究设计与关键结果
- 本指南由加拿大妇产科医师学会制定,内容与推荐由作者起草并达成一致,经加拿大妇科肿瘤学会执行委员会和董事会审阅并提交意见,最终由加拿大妇产科医师学会董事会批准发表。
- 证据质量采用GRADE方法框架评级,推荐等级见原文括号内标注。
- 检索2002年起相关研究,数据库包括Embase、MEDLINE、Cochrane中央对照试验注册库和Cochrane系统评价,初始检索2017年4月,更新至2019年5月,共识别673项研究,引用79项。
证据类型、等级与局限
- 证据类型为指南,采用GRADE方法框架评级证据质量和推荐强度。
- 证据检索优先顺序为荟萃分析、系统评价、指南、随机对照试验、前瞻性队列研究、观察性研究、非系统评价、病例系列和报告。
- 局限:原文未报告局限性。
对床旁实践的改变
- 急诊科医师作为目标用户之一,应识别妊娠滋养细胞疾病并及时转诊妇科评估,妊娠滋养细胞肿瘤应急诊转诊妇科肿瘤专科。
- 妊娠滋养细胞肿瘤应在专科中心治疗并使用集中数据库登记,以捕获和比较这些罕见肿瘤的治疗结局数据并优化患者护理。
指南或共识出处
- 指南名称:Guideline No. 408: Management of Gestational Trophoblastic Diseases;发布机构:加拿大妇产科医师学会(Society of Obstetricians and Gynaecologists of Canada);年份:原文未明确写出。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: This guideline reviews the clinical evaluation and management of gestational trophoblastic diseases, including surgical and medical management of benign, premalignant, and malignant entities. The objective of this guideline is to assist health care providers in promptly diagnosing gestational trophoblastic diseases, to standardize treatment and follow-up, and to ensure early specialized care of patients with malignant or metastatic disease.
INTENDED USERS: General gynaecologists, obstetricians, family physicians, midwives, emergency department physicians, anaesthesiologists, radiologists, pathologists, registered nurses, nurse practitioners, residents, gynaecologic oncologists, medical oncologists, radiation oncologists, surgeons, general practitioners in oncology, oncology nurses, pharmacists, physician assistants, and other health care providers who treat patients with gestational trophoblastic diseases. This guideline is also intended to provide information for interested parties who provide follow-up care for these patients following treatment.
TARGET POPULATION: Women of reproductive age with gestational trophoblastic diseases.
OPTIONS: Women diagnosed with a gestational trophoblastic disease should be referred to a gynaecologist for initial evaluation and consideration for primary surgery (uterine evacuation or hysterectomy) and follow-up. Women diagnosed with gestational trophoblastic neoplasia should be referred to a gynaecologic oncologist for staging, risk scoring, and consideration for primary surgery or systemic therapy (single- or multi-agent chemotherapy) with the potential need for additional therapies. All cases of gestational trophoblastic neoplasia should be discussed at a multidisciplinary cancer case conference and registered in a centralized (regional and/or national) database.
EVIDENCE: Relevant studies from 2002 onwards were searched in Embase, MEDLINE, the Cochrane Central Register of Controlled Trials, and Cochrane Systematic Reviews using the following terms, either alone or in combination: trophoblastic neoplasms, choriocarcinoma, trophoblastic tumor, placental site, gestational trophoblastic disease, hydatidiform mole, drug therapy, surgical therapy, radiotherapy, cure, complications, recurrence, survival, prognosis, pregnancy outcome, disease outcome, treatment outcome, and remission. The initial search was performed in April 2017 and updated in May 2019. Relevant evidence was selected for inclusion in the following order: meta-analyses, systematic reviews, guidelines, randomized controlled trials, prospective cohort studies, observational studies, non-systematic reviews, case series, and reports. Additional significant articles were identified through cross-referencing the identified reviews. The total number of studies identified was 673, with 79 studies cited in this review.
VALIDATION METHODS: The content and recommendations were drafted and agreed upon by the authors. The Executive and Board of Directors of the Society of Gynecologic Oncology of Canada reviewed the content and submitted comments for consideration, and the Board of Directors for the Society of Obstetricians and Gynaecologists of Canada approved the final draft for publication. The quality of evidence was rated using the criteria described in the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology framework. See the online appendix tables for key to grading and interpretation of recommendations.
BENEFITS: These guidelines will assist physicians in promptly diagnosing gestational trophoblastic diseases and urgently referring patients diagnosed with gestational trophoblastic neoplasia to gynaecologic oncology for specialized management. Treating gestational trophoblastic neoplasia in specialized centres with the use of centralized databases allows for capturing and comparing data on treatment outcomes of patients with these rare tumours and for optimizing patient care.
SUMMARY STATEMENTS (GRADE RATINGS IN PARENTHESES): RECOMMENDATIONS (GRADE RATINGS IN PARENTHESES).
参考来源
- Eiriksson L, Dean E, Sebastianelli A, et al. Guideline No. 408: Management of Gestational Trophoblastic Diseases. J Obstet Gynaecol Can. 2021. PMID: 33384141. doi:10.1016/j.jogc.2020.03.001
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。